Unlocking Next-Generation Antibody-Based Conjugates through AJICAP Site-Specific Conjugation & Linker Technologies - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Unlocking Next-Generation Antibody-Based Conjugates through AJICAP Site-Specific Conjugation & Linker Technologies

8:30 am - Wednesday 14th October 2026

AJICAP Conjugation: Exploring site-specific chemical conjugation technology enabling precise DAR control, including DAR1 conjugates, in next-generation ADCs
AJICAP Linker: Demonstrating a novel hydrophilic linker technology that enhances stability and versatile synthesis of ADCs with higher DAR
Evaluating AJICAP-derived ADCs exhibiting high in vivo stability in NHP studies, supporting suitability for further development
Beyond Conventional ADCs: Exploring site-specific conjugation of bispecific antibodies and AOCs with biological evaluation

Speakers:

Tomohiro Watanabe

Tomohiro Watanabe

Scientist

Ajinomoto Co., Inc.